These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 10641958)

  • 1. The use of sulphonylureas in the elderly.
    Graal MB; Wolffenbuttel BH
    Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M
    Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
    Matthews DR; Cull CA; Stratton IM; Holman RR; Turner RC
    Diabet Med; 1998 Apr; 15(4):297-303. PubMed ID: 9585394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative tolerability of sulphonylureas in diabetes mellitus.
    Harrower AD
    Drug Saf; 2000 Apr; 22(4):313-20. PubMed ID: 10789825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
    Pearson ER; Liddell WG; Shepherd M; Corrall RJ; Hattersley AT
    Diabet Med; 2000 Jul; 17(7):543-5. PubMed ID: 10972586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
    Melander A; Bitzén PO; Faber O; Groop L
    Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a concentration-effect relationship for sulphonylureas?
    Melander A; Donnelly R; Rydberg T
    Clin Pharmacokinet; 1998 Mar; 34(3):181-8. PubMed ID: 9533980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of type 2 diabetes mellitus in the elderly: special considerations.
    Rosenstock J
    Drugs Aging; 2001; 18(1):31-44. PubMed ID: 11232737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.